REG - Avacta Group PLC - Posting of Annual Report and Notice of AGM

AvactaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260529:nRSc1142Ga&default-theme=true

RNS Number : 1142G  Avacta Group PLC  29 May 2026

 

Posting of Annual Report and Notice of AGM

 

 

LONDON and PHILADELPHIA - May 29, 2026 - Avacta Therapeutics (AIM: AVCT, "the
Company", "Avacta"), a clinical stage biopharmaceutical company developing
pre|CISION(®), a tumor-activated oncology delivery platform, today announces
that its Annual Report and Accounts for the year ended December 31, 2025 and
the Notice of Annual General Meeting (AGM) are available on the Company's
website (https://avacta.com/investors/investor-resources) .

 

Copies of the Annual Report and Accounts and the Notice of AGM will be posted
today to registered shareholders who have elected to receive them in paper
form.

 

The AGM will be held on Monday, June 22, 2026 at 9:00 BST. The meeting will be
held at Glaziers Hall, 9 Montague Close, London Bridge, SE1 9DD (the "Venue").

 

Registered shareholders have a right to attend the AGM.  In addition, the
current expectation is that the chair of the AGM will, at their discretion,
permit beneficial shareholders to attend in person. Shareholders (registered
or beneficial) who propose to attend the AGM in person are requested to
pre-register their interest and, to assist the Company in its preparation for
the AGM, prove their shareholding by emailing their letter of representation
to investors@avacta.com (mailto:investors@avacta.com) 8.00 p.m. on 20 June
2026. Any failure to pre-register will not, of itself, preclude a registered
shareholder from attending the AGM in person (or by proxy).

 

Only registered shareholders who attend in person or by proxy will be able to
vote on the day. Details of how to submit a proxy vote are contained in the
Notice of the AGM.

 

The Company will provide a business update following the AGM, which will be
recorded and uploaded on the Company's website for shareholders who are not
able to attend in person.  All presentation materials will be made available
on the website at the end of the day and no new material information will be
provided.

 

 

-Ends-

 

For further information from Avacta, please contact:

 

 Avacta Group plc                                   https://avacta.com/ (https://avacta.com/)

 Christina Coughlin, Chief Executive Officer        via Cohesion Bureau

 Strand Hanson Limited (Nominated Adviser)          www.strandhanson.co.uk (http://www.strandhanson.co.uk)

 James Harris / Chris Raggett / James Dance

 Zeus (Broker)                                      www.zeuscapital.co.uk (http://www.zeuscapital.co.uk)

 James Hornigold / George Duxberry / Dominic King

 Cohesion Bureau                                    avacta@cohesionbureau.com (mailto:avacta@cohesionbureau.com)

 Communications / Media / Investors

 Richard Jarvis

 

About Avacta - https://avacta.com/ (https://avacta.com/)

Avacta Therapeutics is a clinical-stage life sciences company expanding the
reach of highly potent cancer therapies through its proprietary pre|CISION®
platform. pre|CISION® is a payload delivery system based on a tumor-specific
protease (Fibroblast Activation Protein or FAP) that is designed to
concentrate highly potent payloads in the tumor microenvironment while sparing
normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC)
are a novel entry to the XDC drug class, leveraging the success of antibody
drug conjugates with alternative methods of delivery beyond antibodies.

 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to
provide unique benefits over traditional antibody drug conjugates, releasing
active payload in the tumor and reducing systemic exposure and toxicity which
enables dosing to be optimized to deliver the best outcomes for patients. The
lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled
pre|CISION® version of doxorubicin that delivers the payload directly in the
tumor with limited peripheral blood exposure and has demonstrated preliminary
activity in tumor types sensitive to doxorubicin including salivary gland
cancer and soft tissue sarcoma.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOAPPUUCAUPQGCR



            Copyright 2019 Regulatory News Service, all rights reserved